normative

FDA Should Demand Efficacy Evidence Eventually

Rather than blocking access, the FDA can reasonably approve a needed drug on surrogate-endpoint evidence, but it should require that studies of real clinical endpoints be ongoing at the time of approval; the problem is these confirmatory studies often never get done, leaving us using therapies that might not work.

normativepending

Speaker

Adam Cifu

Evidence Quote

“we never get that final data, and we are left with, you know, using therapies that might work but we are not sure they do.”

Source

Adam Cifu on Ending Medical Reversal— EconTalk
Created: 6/13/2026, 12:11:12 AM

Your notes

Loading notes...